In this articlePFEFollow your favorite stocksCREATE FREE ACCOUNTJakub Porzycki | Nurphoto | Getty ImagesPfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefitting from its broad cost-cutting program and strong sales of its non-Covid products.The company now expects to book adjusted earnings of $2.15 to $2.35 per share for the fiscal year, up from its prior guidance of $2.05 to $2.25 per share. Pfizer reiterated its previous revenue forecast of $58.5 billion and $61.5 billion, which it first outlined in mid-December. The pharmaceutical giant said its new profit guidance accounts for its “confidence” in its business and its ability to slash costs. Pfizer said it is on track to deliver at least $4 billion in savings by the end of the year.Pfizer’s first-quarter results also benefitted from a smaller-than-feared drop in sales for its Covid antiviral pill Paxlovid.The results come as Pfizer tries to regain its footing after the rapid decline of its Covid business. Demand for those products has plunged to new lows, and they transitioned to the commercial market in the U.S. last year. As revenue suffers, the company is trying to improve its bottom line and shore up investor confidence through its cost cuts and a renewed focus on treating cancer following its $43 billion acquisition of Seagen last year. Here’s what Pfizer reported for the first quarter compared to what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: 82 cents adjusted, it was not immediately clear if it is comparable to the 52 cents expected.Revenue: $14.88 billion vs. $14.01 billion expected.Pfizer recorded first-quarter revenue of $14.88 billion, down 20% from the same period a year ago, primarily due to the plunge in sales of its Covid products.For the first quarter, Pfizer booked a net income of $3.12 billion, or 55 cents per share. That compares to a net income of $5.54 billion, or 97 cents per share, during the same period a year ago. Excluding certain items, the company posted earnings per share of 82 cents for the quarter. Notably, the company said its adjusted and non-adjusted profit got an 11 cents per share boost from a $771 million final adjustment to the estimated $3.5 billion revenue reversal recorded in the fourth quarter, reflecting 5.1 million courses of Paxlovid returned by the U.S. government by Feb. 29. Paxlovid booked $2 billion in revenue for the quarter, down 50% from the same period a year ago. That decline was mainly due to lower deliveries around the world as the product transitioned to commercial market sales, along with lower demand in China. Meanwhile, Pfizer’s Covid vaccine generated $354 million in sales, down 88% from the year-earlier period. That drop was also driven by lower contract deliveries and demand in international markets, as well …
Article Attribution | Read More at Article Source
[mwai_chat context=”Let’s have a discussion about this article:nnIn this articlePFEFollow your favorite stocksCREATE FREE ACCOUNTJakub Porzycki | Nurphoto | Getty ImagesPfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefitting from its broad cost-cutting program and strong sales of its non-Covid products.The company now expects to book adjusted earnings of $2.15 to $2.35 per share for the fiscal year, up from its prior guidance of $2.05 to $2.25 per share. Pfizer reiterated its previous revenue forecast of $58.5 billion and $61.5 billion, which it first outlined in mid-December. The pharmaceutical giant said its new profit guidance accounts for its “confidence” in its business and its ability to slash costs. Pfizer said it is on track to deliver at least $4 billion in savings by the end of the year.Pfizer’s first-quarter results also benefitted from a smaller-than-feared drop in sales for its Covid antiviral pill Paxlovid.The results come as Pfizer tries to regain its footing after the rapid decline of its Covid business. Demand for those products has plunged to new lows, and they transitioned to the commercial market in the U.S. last year. As revenue suffers, the company is trying to improve its bottom line and shore up investor confidence through its cost cuts and a renewed focus on treating cancer following its $43 billion acquisition of Seagen last year. Here’s what Pfizer reported for the first quarter compared to what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: 82 cents adjusted, it was not immediately clear if it is comparable to the 52 cents expected.Revenue: $14.88 billion vs. $14.01 billion expected.Pfizer recorded first-quarter revenue of $14.88 billion, down 20% from the same period a year ago, primarily due to the plunge in sales of its Covid products.For the first quarter, Pfizer booked a net income of $3.12 billion, or 55 cents per share. That compares to a net income of $5.54 billion, or 97 cents per share, during the same period a year ago. Excluding certain items, the company posted earnings per share of 82 cents for the quarter. Notably, the company said its adjusted and non-adjusted profit got an 11 cents per share boost from a $771 million final adjustment to the estimated $3.5 billion revenue reversal recorded in the fourth quarter, reflecting 5.1 million courses of Paxlovid returned by the U.S. government by Feb. 29. Paxlovid booked $2 billion in revenue for the quarter, down 50% from the same period a year ago. That decline was mainly due to lower deliveries around the world as the product transitioned to commercial market sales, along with lower demand in China. Meanwhile, Pfizer’s Covid vaccine generated $354 million in sales, down 88% from the year-earlier period. That drop was also driven by lower contract deliveries and demand in international markets, as well …nnDiscussion:nn” ai_name=”RocketNews AI: ” start_sentence=”Can I tell you more about this article?” text_input_placeholder=”Type ‘Yes'”]
